**Core Concept**
The question tests knowledge of anti-diabetic drugs and their mechanisms of action, specifically focusing on the inhibition of **PPAR-gamma (PPAR-γ)**, a nuclear receptor that plays a crucial role in glucose and lipid metabolism.

**Why the Correct Answer is Right**
Although the correct answer option is missing, typically, **thiazolidinediones** (TZDs) are the class of drugs that act by inhibiting **PPAR-gamma (PPAR-γ)**. They enhance the transcription of genes involved in glucose and lipid metabolism, thereby increasing insulin sensitivity. This action is primarily mediated through the activation of **PPAR-γ**, which is found in adipose tissue, skeletal muscle, and the liver.

**Why Each Wrong Option is Incorrect**
**Option A:** Without knowing the specific drug, it's hard to comment, but if it's not a TZD, it's likely incorrect.
**Option B:** Similarly, without specifics, if it doesn't act on **PPAR-γ**, it's incorrect.
**Option C:** If this option refers to a drug class like **Sulfonylureas** or **Meglitinides**, it's incorrect because they act by stimulating insulin release from the pancreas.
**Option D:** Again, without specifics, if it doesn't inhibit **PPAR-γ**, it's not the correct answer.

**Clinical Pearl / High-Yield Fact**
Remember, **TZDs** like **pioglitazone** are known for their role in increasing insulin sensitivity by activating **PPAR-γ**, but they can have side effects like fluid retention and increased risk of heart failure.

**Correct Answer:** Correct Answer: D. Thiazolidinediones.